SC144 (hydrochloride)
Based on 10 publication(s) in Google Scholar
SC144 hydrochloride is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 hydrochloride binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 hydrochloride shows potent inhibition of gp130 ligand-triggered signaling. SC144 hydrochloride induces apoptosis in human ovarian cancer cells.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.98%
- CAS 番号: 917497-70-2
- 分子式: C16H12ClFN6O
- 分子量:358.76
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Differentiation Inducing Compound Library
HY-L038
-
Orally Active Compound Library
HY-L061
-
Angiogenesis-Related Compound Library
HY-L088
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cytokine Inhibitors Library
HY-L161
-
Cell Death Library
HY-L162
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Posttranslational Modification Library
HY-L226
MedChemExpress（MCE）の使用を引用している文献 SC144 hydrochloride
More- Nat Med. 2024 Jun;30(6):1696-1710. [Abstract]
- Sci Adv. 2023 Jul 21;9(29):eadh0102. [Abstract]
- ACS Appl Mater Interfaces. 2024 Jun 19;16(24):30685-30702. [Abstract]
- Cell Rep. 2025 Aug 7;44(8):116114. [Abstract]
- J Invest Dermatol. 2024 Nov;144(11):2453-2464.e11. [Abstract]
- Biomater Adv. 2026 Jul:184:214814. [Abstract]
- Inflamm Res. 2023 Mar;72(3):493-507. [Abstract]
- Odontology. 2025 Jul;113(3):1081-1091. [Abstract]
- Biochem Biophys Res Commun. 2023 Dec 3:684:149068. [Abstract]
- bioRxiv. 2025 Nov 19.
Customer Validation & Images
-
IF
-
IHC
-
Histological Imaging/Staining
-
IF
-
WB
生物活性
|
IL6-beta |
SC144 inhibits cell growth in a panel of human ovarian cancer cell lines with IC50s in a submicromolar range (IC50=OVCAR-8, OVCAR-5, OVCAR-3= 0.72, 0.49, 0.95 μM)[1].
The potency of SC144 toward NCI/ADR-RES (Paclitaxel- and Doxorubicin-resistant, IC50=0.43 μM) and HEY (Cisplatin-resistant, IC50=0.88 μM) suggests an ability to overcome drug resistance in ovarian cancer[1].
SC144 (2 μM; 24 hours) causes significantly more apoptosis in OVCAR-8 and Caov-3 than normal kidney epithelial and normal endometrial cells[1].
SC144 (0.5-2 μM; 0-6 hours) substantially increases the phosphorylation of gp130 (S782) in both OVCAR-8 and Caov-3 cells in a time- and dose-dependent manner[1].
SC144 is cytotoxic to ovarian cancer cells via a mechanism involving the inhibition of gp130 activity, leading to the inactivation of Akt and Stat3 as well as the suppression of Stat3-regulated gene expression. As are result, SC144 treatment eventually causes cell-cycle arrest, anti-angiogenesis, and apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:OVCAR-8 and Caov-3 cells
-
Concentration:2 μM
-
Incubation Time:24 hours
-
Result:Significantly caused cell death in OVCAR-8 and Caov-3 cells.
-
Cell Line:OVCAR-8, Caov-3 cells
-
Concentration:0.5-2 μM
-
Incubation Time:0-6 hours
-
Result:Substantially increased the phosphorylation of gp130 (S782) in both OVCAR-8 and Caov-3 cellsin a time- and dose-dependent manner.
SC144 (100 mg/kg; p.o.; daily for 35 days) treatment shows the average tumor volume in mice 82% smaller than that in the control group[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic mice (human ovarian cancer xenograft)[1]
-
Dosage:I.p; daily for 58 days
-
Administration:10 mg/kg
-
Result:Significantly inhibited tumor growth by about 73%.
化学情報
-
CAS 番号 917497-70-2
-
性状 Solid
-
分子量 358.76
-
分子式 C16H12ClFN6O
-
Color Light yellow to gray
-
SMILES
O=C(C1=NC=CN=C1)NNC2=NC3=C(N4C2=CC=C4)C=CC(F)=C3.[H]Cl
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Med
Multiomic analyses uncover immunological signatures in acute and chronic coronary syndromes. [Abstract]2024 Jun;30(6):1696-1710. PMID: 38773340 -
Sci Adv
The astrocytic TRPA1 channel mediates an intrinsic protective response to vascular cognitive impairment via LIF production. [Abstract]2023 Jul 21;9(29):eadh0102. PMID: 37478173
SC144 hydrochloride purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jul 21;9(29):eadh0102. [Abstract]
SC144 (10 mg/kg). Representative image of myelin staining of the corpus callosum on postoperative day 14.
-
ACS Appl Mater Interfaces
Mg-Cross-Linked Alginate Hydrogel Induces BMSC/Macrophage Crosstalk to Enhance Bone Tissue Regeneration via Dual Promotion of the Ligand-Receptor Pairing of the OSM/miR-370-3p-gp130 Signaling Pathway. [Abstract]2024 Jun 19;16(24):30685-30702. PMID: 38859670 -
Cell Rep
2025 Aug 7;44(8):116114. PMID: 40782349
SC144 hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Aug 7;44(8):116114. [Abstract]
Representative IF staining of pSTAT3 (red) and PDGFRA (green) in Il4rafl/fl and Il4raΔPdgfra with vehicle or SC144 (10 mg/kg) in d7 MC903, quantified at right.
-
J Invest Dermatol
E3 Ubiquitin Ligase NEDD4L Negatively Regulates Skin Tumorigenesis by Inhibiting IL-6/GP130 Signaling Pathway. [Abstract]2024 Nov;144(11):2453-2464.e11. PMID: 38580105
SC144 hydrochloride purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2024 Nov;144(11):2453-2464.e11. [Abstract]
Quantitative standardized immunohistochemical (IHC) analysis showed that keratinocyte-specific knockout of Nedd4l significantly promoted the expression of Ki-67, p-STAT3 (Y705) and cyclin D1 in tumor tissues; however, administration of SC144 (10 mg/kg) completely eliminated these effects.
SC144 hydrochloride purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2024 Nov;144(11):2453-2464.e11. [Abstract]
Representative images for H&E staining of papilloma and cSCC tissues in WT and Nedd4l-cKO mice treated with or without SC144 (10 mg/kg). Arrows indicate keratin pearl.
-
Biomater Adv
Optimal Se content on P/G-EGCG@Se nanofibers reverses muscle-derived IL-6- induced osteogenesis depression. [Abstract]2026 Jul:184:214814. PMID: 41832820 -
Inflamm Res
Inhibition of gp130 alleviates LPS-induced lung injury by attenuating apoptosis and inflammation through JAK1/STAT3 signaling pathway. [Abstract]2023 Mar;72(3):493-507. PMID: 36617342
SC144 hydrochloride purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2023 Mar;72(3):493-507. [Abstract]
SC144 (20 mg/kg; dissolved in DMSO; i.p.; single) significantly inhibits the expression of gp130 in mouse lung tissue.
SC144 hydrochloride purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2023 Mar;72(3):493-507. [Abstract]
RT-PCR was used to analyze the relative expression levels of IL-6 mRNA (20 mg/kg) in mouse lung tissue after LPS and SC144 treatment.
-
Odontology
Transcriptional regulation of human follicular dendritic cell-secreted protein gene by interleukin-6. [Abstract]2025 Jul;113(3):1081-1091. PMID: 39776305 -
Biochem Biophys Res Commun
2023 Dec 3:684:149068. PMID: 37866240 -
溶剤 & 溶解度
DMSO : 10 mg/mL (27.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7874 mL | 13.9369 mL | 27.8738 mL | 69.6845 mL |
| 5 mM | 0.5575 mL | 2.7874 mL | 5.5748 mL | 13.9369 mL | |
| 10 mM | 0.2787 mL | 1.3937 mL | 2.7874 mL | 6.9684 mL | |
| 15 mM | 0.1858 mL | 0.9291 mL | 1.8583 mL | 4.6456 mL | |
| 20 mM | 0.1394 mL | 0.6968 mL | 1.3937 mL | 3.4842 mL | |
| 25 mM | 0.1115 mL | 0.5575 mL | 1.1150 mL | 2.7874 mL |
SC144 hydrochloride 関連分類
HY-15614A 関連分類
Powered by Bioz